Minimally Invasive Vertebral Compression Fracture Treatments | Global | 2018 | Market Analysis
The global MIVCF treatment device market will be driven mainly by the growing aging and obese population across the globe. Furthermore, new product launches and increasing adoption of advanced premium-priced technologies will help overcome obstacles such as unfavorable reimbursement environments. Therefore, the market will see moderate growth through 2026.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for MIVCF treatment devices in the global region across a 10-year period.
The global MIVCF treatment market will grow moderately through 2026, with MNCs dominating the market and mergers and acquisitions remaining common.
Which companies are the largest competitors in each of the MIVCF treatment markets in the global region?
What factors contribute to the success of these competitors in the global MIVCF treatment market?
What can local and international competitors do to succeed in this market?
What recent mergers and acquisitions have taken place, and how do they affect market shares?
The continuing introduction of products and expanded indications in the MIVCF treatment market will drive market growth.
How will the introduction of new products enable manufacturers to mitigate negative pricing trends and maintain profit margins?
How quickly will the MIVCF market expand in the global region following the anticipated approval of new indications?
The unfavorable reimbursement environments and strong cost constraints experienced by health care facilities globally, particularly in Europe, will hinder the adoption of premium-priced MIVCF treatment devices.
Which devices will be most impacted by this trend?
What strategies will companies use to remain competitive despite these challenges?
Changing MIVCF treatment reimbursement landscapes in the Asia Pacific region have strongly impacted market dynamics.
How have changes to reimbursement in Australia, Japan, and South Korea affected the growth of MIVCF treatments performed in those regions?
Which of the countries represents the greatest opportunity for growth in the Asia Pacific region?
What strategies are competitors using to expand product penetration and market share when reimbursement is lacking?
